

This listing of claims will replace all prior versions, and listings, of claims in the application.

### Amendments to the Claims

1-75. (Previously Canceled)

76-87. (Canceled)

88. (Currently Amended) A composition comprising at least one of a chemotherapeutic agent or a radiosensitizer agent, and further comprising a diagnostic or therapeutic ~~The composition of claim 77, wherein the metallopharmaceutical~~ which is selected from the group consisting of is:

<sup>99m</sup>Tc (((4-(4-(((3-(2-(2-(3-((6-(diazenido)(3-pyridyl))carbonylamino)propoxy)ethoxy)ethoxy)propyl)amino)sulfonyl)phenyl)phenyl)sulfonyl)amino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonylamino)propanoic acid) (tricine)(TPPTS);

<sup>99m</sup>Tc (2-(2-((5-(N-(1,3-bis(3-(2-(2-(3-(((4-(4-(((1-carboxy-2-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonylamino)ethyl)amino)sulfonyl)phenyl)phenyl)sulfonyl)amino)propoxy)ethoxy)ethoxy)propyl)carbamo yl)propyl)carbamo yl)(2-pyridyl))2-diazenido) (tricine)(TPPTS);

<sup>99m</sup>Tc (2-((6-(diazenido)(3-pyridyl))carbonylamino)-4-(N-(3-(2-(2-(3-(((4-(4-(((1-carboxy-2-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonylamino)ethyl)amino)sulfonyl)phenyl)phenyl)sulfonyl)amino)propoxy)ethoxy)ethoxy)propyl)carbamo yl)butanoic acid) (tricine)(TPPTS);


<sup>99m</sup>Tc (2-(6-((6-(diazenido)(3-pyridyl))carbonylamino)hexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonylamino)-propanoic acid) (tricine)(TPPTS);


<sup>99m</sup>Tc (2-((6-(diazenido)(3-pyridyl))carbonylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonylamino)propanoic acid (tricine)(TPPTS);

<sup>99m</sup>Tc [2-[[[5-[carbonyl]-2-pyridinyl]diazenido]-Glu(2-(6-aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid)(2-(6-aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid)) (tricine)(TPPTS); or

<sup>99m</sup>Tc ([2-[[[5-[carbonyl]-2-pyridinyl]diazenido]-Glu-bis-[Glu(2-(6-aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid)(2-(6-aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid)]] (tricine)(TPPTS).


89. (Currently Amended) A composition comprising at least one of a chemotherapeutic agent or a radiosensitizer agent, and further comprising a diagnostic or therapeutic ~~The composition of claim 77, wherein~~  
the metallopharmaceutical which is selected from the group consisting of is:









90-93. (Canceled)

94. (Currently Amended) A composition comprising at least one of a chemotherapeutic agent or a radiosensitizer agent, and further comprising a diagnostic or therapeutic ~~The composition of claim 77, wherein~~ the metallopharmaceutical which is selected from the group consisting of is:




95. (Currently Amended) A composition comprising at least one of a chemotherapeutic agent or a radiosensitizer agent, and further comprising a diagnostic or therapeutic ~~The composition of claim 77, wherein~~ the metallopharmaceutical which is selected from the group consisting of is:





96-98. (Canceled)

99. (Currently Amended) A composition comprising at least one of a chemotherapeutic agent or a radiosensitizer agent, and further comprising a diagnostic or therapeutic ~~The composition of claim 77, wherein~~ the metallopharmaceutical which is selected from the group consisting of is:



100-106 (Canceled)

107. (Previously Canceled)

108-110. (Canceled)